ABSK-021 is a small molecule commercialized by Abbisko Therapeutics, with a leading Phase I program in Tenosynovial Giant Cell Tumor. According to Globaldata, it is involved in 5 clinical trials, of which 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of ABSK-021’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ABSK-021 is expected to reach an annual total of $42 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ABSK-021 is under development for the treatment of advanced malignancies, tenosynovial giant cell tumors (TGCT), pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, small cell lung cancer and other solid tumors, chronic graft versus host disease (GvHD) and amyotrophic lateral sclerosis (ALS). The therapeutic candidate is formulated as capsule and administered through oral route. It is acts by targeting CSF1R.
Abbisko Therapeutics Overview
Abbisko Therapeutics (Abbisko) is a biopharmaceutical company. It discovers and develops of novel medicines to the treatment of cancers and other diseases. Its pipeline products include ABSK011, ABSK021 among others. ABSK011 developed for the treatment of advanced HCC with hyperactivation of FGF19/FGFR4 signaling. ABSK021 is for the treatment of adult patients with TGCT, pancreatic cancer, colorectal cancer, cGvHD and ALS. It offers services such as drug discovery development and clinical trials. It owns an integrated research and development center in Shanghai Zhangjiang Hi-Tech Park to conduct immune-oncology drug development activities. Abbisko is headquartered in Shanghai, China.
The operating loss of the company was CNY492.9 million in FY2022, compared to an operating loss of CNY1,809 million in FY2021. The net loss of the company was CNY495.6 million in FY2022, compared to a net loss of CNY1,810 million in FY2021.
For a complete picture of ABSK-021’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.